GTHX

G1 Therapeutics, Inc. (GTHX) | Rumor.io

G1 Therapeutics

GTHX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about GTHX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 8

$GTHX has seen an 81% increase in value.
G1 Therapeutics has reported a loss of $0.10, beating consensus estimates of ($0.17).
The company's stock price has been upgraded to 7.15 by Wainwright.

Generated by AI

Sentiment

Of the messages about GTHX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	71.43% -11.2
Bearish	—	—	—	28.57% +11.2

Bullish· Aug 7

The asset's price increased by 60% premarket on news, reaching a total equity value of approximately $405 million.
The company's shareholders will receive $7.15 per share in cash, a significant return on investment for those who held long positions.
The asset's performance has been impressive, with some investors making a healthy profit, including one who made $300k and another who grabbed calls for their mom when unusual options activity was detected.

Bearish· Jun 24

The company's Phase 3 trial, PRESERVE 2, has failed, and the company plans to wind down the trial and make significant headcount reductions.
The results of the Phase 3 trial were significantly worse than those of the Phase 2 trial, with the treatment showing little to no benefit over a placebo.
The company's stock has taken a significant hit, with a decline of over 50% in some cases, and some analysts are warning of potential buying opportunities due to the stock's oversold status.

Generated by AI

Topics

Of the messages about GTHX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	75%
Controversies	—	—	—	25%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Nov 5

G1 Therapeutics, Inc. ($GTHX) reported a Q3 loss of $0.86 per share, missing the consensus estimate by $0.01.
The company's cash and equivalents stood at $299.93M.
G1 Therapeutics' Q3 earnings report provided a sneak peek at the company's performance.

Analysts· Jan 30

Analysts are upgrading G1 Therapeutics (GTHX) with multiple price target increases, including a raise from $7 to $10 by JP Morgan.
The buy consensus among 13 analysts is at 82%, indicating high confidence in the stock.
JPMorgan analyst Anupam Rama has a history of accurate recommendations, with investors who followed his advice receiving a 29% return in the past year, compared to a negative 27% return on the shares.

Announcements· Aug 7

Pharmacosmos Group to acquire G1 Therapeutics for $7.15 per share in cash, with a total equity value of approximately $405 million.
The acquisition is expected to provide patients with extensive stage small cell lung cancer optimal access to G1's COSELA (trilaciclib), a proactive multilineage myeloprotection agent.
The transaction expands and strengthens Pharmacosmos' global commercial portfolio, with G1's shareholders to receive $7.15 per share in cash.

Generated by AI

Community

Of the messages about GTHX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	34.88%
Newcomers	—	—	—	65.12%

Regulars· Jun 24

The Phase 3 PRESERVE 2 trial for G1 Therapeutics' trilaciclib in metastatic triple-negative breast cancer (mTNBC) did not achieve statistical significance in the primary endpoint of overall survival (OS).
The company plans to wind down the PRESERVE 2 trial and discontinue hiring for a first-line treatment indication, instead focusing on the ES-SCLC market and streamlining operations.
G1 Therapeutics' stock price declined significantly, with the company trading at 298% above average volume and a 25% decrease in value, prompting some to call for the company to be sold and its shares to be liquidated.

Newcomers· May 9

Many newcomers are focused on the potential for $GTHX to experience a statistically worse overall survival rate, which could impact its market value.
The takeover speculation surrounding G1 Therapeutics, Inc. is being closely watched, with some users expecting a positive outcome that could boost the stock's price.
New investors are attracted to $GTHX due to its high volatility, which could lead to new highs in the coming months, and a stronger balance sheet.

Generated by AI

Also Discussed

Investors talking about GTHX also mention

#	Name	Attention
1	Karyopharm Therapeutics Inc.KPTI	0%new
2	SWTX - SpringWorks Therapeutics, Inc.	——
3	MYOV - Myovant Sciences Ltd.	——
4	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
5	ALRN - Aileron Therapeutics, Inc.	——
6	MRTX - Mirati Therapeutics, Inc.	——
7	Heron Therapeutics, Inc.HRTX	0%+0
8	KALA BIO, Inc.KALA	0.02%new
9	BPMC - Blueprint Medicines Corporation	——
10	Precision BioSciences, Inc.DTIL	0%new

G1 Therapeutics, Inc.

Location

Social

What share of all stock conversation is about GTHX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 8

$GTHX has seen an 81% increase in value.
G1 Therapeutics has reported a loss of $0.10, beating consensus estimates of ($0.17).
The company's stock price has been upgraded to 7.15 by Wainwright.

Generated by AI

Sentiment

Of the messages about GTHX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	71.43% -11.2
Bearish	—	—	—	28.57% +11.2

Bullish· Aug 7

The asset's price increased by 60% premarket on news, reaching a total equity value of approximately $405 million.
The company's shareholders will receive $7.15 per share in cash, a significant return on investment for those who held long positions.
The asset's performance has been impressive, with some investors making a healthy profit, including one who made $300k and another who grabbed calls for their mom when unusual options activity was detected.

Bearish· Jun 24

The company's Phase 3 trial, PRESERVE 2, has failed, and the company plans to wind down the trial and make significant headcount reductions.
The results of the Phase 3 trial were significantly worse than those of the Phase 2 trial, with the treatment showing little to no benefit over a placebo.
The company's stock has taken a significant hit, with a decline of over 50% in some cases, and some analysts are warning of potential buying opportunities due to the stock's oversold status.

Generated by AI

Topics

Of the messages about GTHX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	75%
Controversies	—	—	—	25%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Nov 5

G1 Therapeutics, Inc. ($GTHX) reported a Q3 loss of $0.86 per share, missing the consensus estimate by $0.01.
The company's cash and equivalents stood at $299.93M.
G1 Therapeutics' Q3 earnings report provided a sneak peek at the company's performance.

Analysts· Jan 30

Analysts are upgrading G1 Therapeutics (GTHX) with multiple price target increases, including a raise from $7 to $10 by JP Morgan.
The buy consensus among 13 analysts is at 82%, indicating high confidence in the stock.
JPMorgan analyst Anupam Rama has a history of accurate recommendations, with investors who followed his advice receiving a 29% return in the past year, compared to a negative 27% return on the shares.

Announcements· Aug 7

Pharmacosmos Group to acquire G1 Therapeutics for $7.15 per share in cash, with a total equity value of approximately $405 million.
The acquisition is expected to provide patients with extensive stage small cell lung cancer optimal access to G1's COSELA (trilaciclib), a proactive multilineage myeloprotection agent.
The transaction expands and strengthens Pharmacosmos' global commercial portfolio, with G1's shareholders to receive $7.15 per share in cash.

Generated by AI

Community

Of the messages about GTHX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	34.88%
Newcomers	—	—	—	65.12%

Regulars· Jun 24

The Phase 3 PRESERVE 2 trial for G1 Therapeutics' trilaciclib in metastatic triple-negative breast cancer (mTNBC) did not achieve statistical significance in the primary endpoint of overall survival (OS).
The company plans to wind down the PRESERVE 2 trial and discontinue hiring for a first-line treatment indication, instead focusing on the ES-SCLC market and streamlining operations.
G1 Therapeutics' stock price declined significantly, with the company trading at 298% above average volume and a 25% decrease in value, prompting some to call for the company to be sold and its shares to be liquidated.

Newcomers· May 9

Many newcomers are focused on the potential for $GTHX to experience a statistically worse overall survival rate, which could impact its market value.
The takeover speculation surrounding G1 Therapeutics, Inc. is being closely watched, with some users expecting a positive outcome that could boost the stock's price.
New investors are attracted to $GTHX due to its high volatility, which could lead to new highs in the coming months, and a stronger balance sheet.

Generated by AI

G1 Therapeutics

Social

Aug 8

Sentiment

Bullish· Aug 7

Bearish· Jun 24

Topics

Earnings· Nov 5

Analysts· Jan 30

Announcements· Aug 7

Community

Regulars· Jun 24

Newcomers· May 9

Also Discussed

G1 Therapeutics, Inc.

Company Information

Location

Also Discussed

Social

Aug 8

Sentiment

Bullish· Aug 7

Bearish· Jun 24

Topics

Earnings· Nov 5

Analysts· Jan 30

Announcements· Aug 7

Community

Regulars· Jun 24

Newcomers· May 9